Open Access Article
Hong Zhanga,
Jianyuan Wangb,
Cheng Lic,
Di Zhaoa,
Tianyu Lianga and
Yang Li
*a
aCollege of Chemistry and Materials Engineering, Bohai University, No. 19, Keji Street, Jinzhou, P. R. China. E-mail: bhuzh@163.com
bDepartment of Chemical Engineering, Fushun Teacher's College, No. 103, Wenhua Street, Fushun, P. R. China
cLiaoyang Ecological Environment Monitoring Center, Liaoyang, P. R. China
First published on 23rd August 2024
In this work, a green, efficient and catalyst-free synthesis of a series of structurally novel (E)-diethyl 2-styrylquinoline-3,4-dicarboxylates via a direct olefination reaction between diethyl 2-methylquinoline-3,4-dicarboxylate and various aromatic aldehydes was successfully accomplished by employing eco-friendly 1,3-dimethylurea/L-(+)-tartaric acid (DMU/LTA) as an inexpensive, non-toxic and reusable reaction medium. This methodology has the attractive advantages of mild reaction conditions, simple experimental operation, and the absence of any dangerous catalysts or unsafe volatile organic solvents, with satisfactory to good yields. Subsequently, a primary in vitro evaluation for their anti-proliferative activity against human cancer cell lines A549, HT29 and T24 revealed that the compound with the 3,4,5-trimethoxystyryl moiety exhibited potent anti-tumor activity with IC50 values of 2.38, 4.52 and 9.86 μmol L−1, respectively, thereby being equipotent or even better than the reference cisplatin.
The conventional approach for the direct olefination of 2-methylquinolines with aldehydes involves the use of acetic anhydride as the reaction medium,14 but the protocol is plagued by constraints such as high reaction temperature, the use of a large excess of aldehydes and low product yields. Owing to the great significance of direct olefination in organic synthesis, great efforts have been devoted during the past decades to develop more convenient and effective synthetic methods, including (1) the utilization of NaOAc as a base in water-acetic acid binary solvents;5 (2) the use of metal catalysts such as La(Pfb)3,15 Fe3O(BPDC)3,16 or Fe(OAc)2
17 in toluene; InCl3 in THF;18 CoCl2 in H2O;19 Ca(OTf)2/Bu4NPF6 under solvent-free conditions;20 and ZnCl2 under microwave irradiation;21 (3) solvent-free microwave irradiation under inert gas atmosphere (N2) at high temperatures (170–175 °C);22 (4) employment of 1,4-dioxane as the reaction medium under catalyst-free conditions at 140 °C;23 and (5) the combination of 1,3-dimethylbarbituric acid and HOAc as synergistic catalysts,24 as summarized in Scheme 1a. Although these elegant methods for the direct olefination of 2-methylquinolines have emerged, they were invariably associated with certain limitations such as harsh reaction conditions; toxic chemical reagents; expensive or unavailable catalysts; and volatile, flammable and harmful organic solvents. In addition, 2-styrylquinolines could also be facilely accessed using 1-methylimidazolium trifluoroacetate ([Hmim]TFA)25 or Brønsted acidic imidazolium ionic liquids as the reaction medium,26 which involved in situ generated 2-methylquinoine from o-aminoketone and β-ketoester, followed by its olefination reaction with aromatic aldehydes. However, the high cost and environmental toxicity have limited their practical application.
Nowadays, in light of the stringent environmental requirements and safety considerations in chemical production, increasing research efforts have been focused on the development of sustainable and environmentally benign reaction procedures to replace those efficient but somewhat outdated methods, particularly, to replace volatile, flammable and harmful organic solvents.27 Deep eutectic solvents (DESs), as an emerging class of unconventional solvents derived from the combination of two or three safe and cheap components of Lewis or Brønsted acids and bases through hydrogen bond formation, have attracted enormous attention due to their unique properties, including a wide liquid range, negligible vapor pressure, low toxicity, non-flammability, high solvation capacity, high biodegradability, low cost of components and convenient preparation,28 thereby rendering them acknowledged widely as an excellent alternative to volatile organic solvents in the development of environmentally friendly organic reactions.29 For example, Zhang's group has developed the application of choline chloride (ChCl)/urea,30 choline chloride/lactic acid (ChCl/LAC),31 choline chloride/glycerol (ChCl/Gly),32 choline chloride (ChCl)/malonic acid,33 and ChCl/L-(+)-tartaric acid34 as a biodegradable, recycled and reusable media in the green synthesis of heterocyclic compounds. Therefore, the synthesis of this class of 2-styrylquinoline derivative using deep eutectic solvents would be highly sought after. There was an impressive report from Kashinath group,35 who described a green, metal-free, one-pot synthesis of 2-styrylquinolines using a combination of 1,3-dimethyl urea (1,3-DMU) and L-tartaric acid (LTA) (in a 3
:
1 ratio) as a deep eutectic solvent (DES) via Friedlander annulation, followed by Knoevenagel condensation, as shown in Scheme 1b. Inspired by the report, our group in this regard has recently achieved the green synthesis of (E)-2-styrylquinoline-3-carboxylic acid by using the non-toxic deep eutectic solvent (DES) of 1,3-dimethylurea (DMU)/L-tartaric acid (LTA) as medium (Scheme 1c).36 In view of the structural diversity playing a prominent role in new drug discovery37 and in the context of our ongoing studies concerning the green synthesis of quinoline derivatives, we envisioned that 2-methylquinoline-3,4-dicarboxylate as a very intriguing scaffold might be amenable to the green strategy to access a new class of 2-styrylquinoline compounds, which might exhibit interesting biological activities. Thus, we would like to report, herein, a new and environmentally benign synthesis and preliminary in vitro anti-tumor activity evaluation of a series of structurally novel diethyl 2-styrylquinoline-3,4-dicarboxylate derivatives by using the safe, eco-friendly and unconventional 1,3-DMU/LTA as a solvent (Scheme 1d). To the best of our knowledge, the green synthesis and biological activity evaluation of such quinoline derivatives has not been achieved so far and might be employed as potential candidates for future drug discovery.
Due to the satisfactory yield obtained and in order to retain the simplicity of the procedure, no further optimization in reaction conditions was necessary. In order to highlight the advantages of the DES solvent, a control experiment was carried out, in which the model reaction was conducted employing the widely used Ac2O as the medium based on the literature method.2 However, from the experiment, product 3a was obtained only in 38% yield. Thus, the use of DMU/LTA as the green reaction medium not only avoids the disadvantages of conventional organic solvents but also results in greatly enhanced reactivity. In addition, it is worth noting that we also carried out the model reaction in the presence of either L-(+)-tartaric acid or 1,3-dimethylurea in some common organic solvents at refluxing temperatures. However, we found that the product formed from these tests was only in a trace amount, as observed by TLC after 24 hours, which suggested that the reaction gave a good yield due to the interaction of DMU/L-(+)-tartaric acid system and not due to its individual component. The reason for the effectiveness of DMU/LTA might be its good solubility, high stability and positive synergic effect on the reaction through extensive hydrogen bonding. Finally, the recyclability of DMU/LTA for the model reaction was investigated by subjecting the fresh substrates 1 and 2a to the recovered DMU/LTA obtained by evaporating the aqueous layer under vacuum after product removal to repeat the model reaction. We found that the recovered DMU/LTA could be re-used up to three consecutive runs, with the 3a yields being 82%, 81% and 77%, respectively, demonstrating negligible changes in the synthetic efficiency, though a slight darkening of the eutectic mixture was observed after recycling. Thus, the DES could be successfully re-used over three cycles with a decrease of 6% in the final 3a yield, and the corresponding E-factor value (total mass of waste/mass of product) from the three re-used cycles was calculated to be 93.68. However, starting from the fourth cycle, an obvious decrease in the product yield of 65% was noticed.
To demonstrate the synthetic potential by applying DMU/LTA as the privileged reaction medium in the Knoevenagel condensation reaction, we extended the reaction to other substituted aromatic aldehydes in a similar fashion. Satisfactorily, these aldehydes were equally amenable to the reaction process without any experimental difficulties, successfully delivering the corresponding 3b–o in satisfactory yields of 61–86%, as listed in Table 1. It is worth noting that in all cases, the acid-sensitive ester and the newly formed olefin groups remain unaffected under the reaction conditions.
| Entry | Compd | Ar | Yielda/% | Mp/°C |
|---|---|---|---|---|
| a Isolated yield. | ||||
| 1 | 3a | Ph | 83 | 92–94 |
| 2 | 3b | 3-MeC6H4 | 82 | 78–79 |
| 3 | 3c | 4-MeC6H4 | 85 | 89–90 |
| 4 | 3d | 2,5-(Me)2C6H3 | 72 | Oily liquid |
| 5 | 3e | 3,4-(Me)2C6H3 | 81 | 108–109 |
| 6 | 3f | 2-MeOC6H4 | 70 | 98–100 |
| 7 | 3g | 3-MeOC6H4 | 78 | Oily liquid |
| 8 | 3h | 2,3-(MeO)2C6H3 | 65 | 72–73 |
| 9 | 3i | 2,5-(MeO)2C6H3 | 67 | Oily liquid |
| 10 | 3j | 3,4-(MeO)2C6H3 | 80 | Oily liquid |
| 11 | 3k | 3,4,5-(MeO)3C6H3 | 83 | Oily liquid |
| 12 | 3l | 2-ClC6H4 | 69 | Oily liquid |
| 13 | 3m | 3-BrC6H4 | 81 | 69–71 |
| 14 | 3n | 2-NO2C6H4 | 61 | 119–120 |
| 15 | 3o | 4-NO2C6H4 | 86 | 161–162 |
As shown in Table 1, the electronic nature of the substituent present in the aromatic aldehydes appeared not to affect the transformation, neither in product yield nor in reaction rate. For example, compound 3c with an electron-donating methyl group and 3o bearing an electron-withdrawing nitro group were obtained in comparable yields of 85% and 86%, respectively, showing little distinction (entries 3 vs. 15, Table 1). Conversely, the site of the substituent present in the aromatic aldehydes had a significant steric hindrance effect on the product yields. The reaction with ortho-substituted aromatic aldehydes generally gave the corresponding products 3d, 3f, 3h, 3i, 3l and 3n in relatively lower yields with longer reaction times compared with those of meta- and para-substituted ones (entries 4, 6, 8, 9, 12 and 14, Table 1). Particularly, we found that the reaction with di-ortho substituted aromatic aldehydes such as 2,6-dimethyl-, 2,6-dimethoxy and 2,6-dihalobenzaldehydes scarcely proceeded, from which the desired products were detected only in negligible amounts that did not warrant isolation. In addition, the reaction with aliphatic aldehydes such as butyraldehyde, iso-butyraldehyde and cyclohexanecarboxaldehyde was also tested. However, the reaction was found to be fraught with difficulties associated with the combination of starting materials and numerous products, from which we could not separate the desired alkenylation products in any appreciable yield.
With the aim of further diversifying our synthetic work, we became interested in seeing whether quinoline aldehydes would exhibit a similar reactivity. To our delight, the two chosen 2-chloroquinoline-3-carbaldehydes were viable substrates for this transformation as well, invariably furnishing the corresponding vinyl-linked bisquinolines 3p and 3q though in low yields of 53% and 51%, respectively, with a longer reaction time of 8 hours, as shown in Scheme 3. Their structures would be very attractive as many bisquinoline derivatives usually exhibit potent biological activities.42 Work is currently ongoing in this regard, and more studies on extending the reaction scope will be part of our future efforts.
To the best of our knowledge, all these newly synthesized products 3a–q have never been reported, and their structures have been explicitly characterized based on their spectral and analytical data. Theoretically, these structures should exist as (E)- and/or (Z)-geometry due to the presence of the exocyclic vinyl double bond. The most diagnostic evidence for the geometry of vinyl moiety was the characteristic resonances of the arising two vinylic proton CH
CH doublets at δ 7.42–7.78 ppm and 8.01–8.38 ppm with large spin–spin coupling constants Jab ∼16.0 Hz in their 1H NMR spectra, which clearly established the stereochemistry of the product as an E-stereoisomer.
Mechanistically, on the basis of the reports from Alvi et al.,43 who recently described the resonance equation of the DES acting as a proton source, and Krishnakumar et al.,44 who determined the structure, thermal stability and pH value of DMU/LTA (7
:
3), a proposed reaction mechanism for the synthesis of the title compounds is outlined in Scheme 4. First, the ability of the acidic DMU/LTA (7
:
3) (pH = 3.7) to N-protonation might play an important role in the activation of 2-methylquinoline 1 to generate the enamine intermediate A. The formed intermediate A could behave as a nucleophile to attack the aromatic aldehydes and give rise to the corresponding adduct B. In this nucleophilic addition reaction, there was a consensus that the DES might also assist in improving the electrophilic reactivity of the aldehydes by hydrogen bonding with its carbonyl group.45 Subsequently, the generated hydroxyl group readily underwent the elimination reaction with the ortho-position hydrogen proton with the loss of one molecule of water to produce the corresponding 2-styrylquinoline derivatives 3. In the sequences of steps, DES played dual roles of solvent and catalyst.
With the series of newly synthesized (E)-diethyl 2-styrylquinoline-3,4-dicarboxylate derivatives in hand, we became interested in evaluating their anti-tumor activity. Thus, a preliminary screening for their in vitro anti-tumor activities against human cancer cell lines A549, HT29 and T24 was conducted by the methylthiazolyldiphenyltetrazolium bromide (MTT) conversion assay using the known anti-cancer cisplatin as a reference drug. As listed in Table 2, the unsubstituted 2-styrylquinoline-3,4-dicarboxyalte (3a) exhibited moderate anti-proliferative activity against A549 and HT29 and poor inhibitory effect towards T24 (entry 1, Table 2). The activity was not further potentiated by the introduction of methyl, chloro, bromo and nitro substituents as in 3b–e and 3l–o (entries 2–5 and 12–15, Table 2), which exhibited moderate inhibitory effects. Interestingly, it was observed that the introduction of methoxy substituent appeared to be beneficial in terms of the anti-tumor activity as in compounds 3f–k, which exhibited superior activity (entries 6–11 Table 2). Moreover, the poly-methoxy substituted ones have higher inhibitory activity than the mono-substituted counterparts, and especially, the compound 3k with the 3,4,5-trimethoxystyryl fragment had the best anti-proliferative activity against A549, HT29 and T24 cell lines with the IC50 values of 2.38, 4.52 and 9.86 μmol L−1, respectively (entry 11, Table 2), being equipotent or even better than the reference cisplatin. Additionally, the vinylene-linked bisquinolines 3p and 3q were also found to exhibit satisfactory inhibition properties against the growth of three tested cancer cell lines (entries 16 and 17, Table 2), having the potential to further exploit new drug discovery.
| Entry | Compd | IC50a/μmol L−1 | ||
|---|---|---|---|---|
| A549b | HT29b | T24b | ||
| a IC50 is defined as the drug concentration causing a 50% decrease in cell population using MTT assay as described in the Experimental section.b Cell lines: A549: human lung tumor; HT29: human colon tumor cells, and T24: human urinary bladder tumor cells. | ||||
| 1 | 3a | 18.47 | 24.86 | >40 |
| 2 | 3b | 20.58 | 30.94 | >40 |
| 3 | 3c | 18.61 | 28.15 | >40 |
| 4 | 3d | 18.15 | 25.92 | 30.88 |
| 5 | 3e | 23.49 | >40 | 35.89 |
| 6 | 3f | 16.85 | 14.12 | >40 |
| 7 | 3g | 8.27 | 13.51 | 18.78 |
| 8 | 3h | 9.27 | 15.76 | 26.43 |
| 9 | 3i | 12.84 | 19.56 | 17.69 |
| 10 | 3j | 5.24 | 10.32 | 15.16 |
| 11 | 3k | 2.38 | 4.52 | 9.86 |
| 12 | 3l | 19.45 | 23.08 | >40 |
| 13 | 3m | 25.40 | 21.34 | 30.61 |
| 14 | 3n | >40 | >40 | >40 |
| 15 | 3o | >40 | >40 | >40 |
| 16 | 3p | 6.79 | 8.04 | 16.55 |
| 17 | 3q | 7.41 | 4.33 | 11.18 |
| 18 | Cisplatin | 2.73 | 6.82 | 7.69 |
It is interesting to mention that some significant anti-tumor agents, such as (E)-5,6,7-trimethoxy-N-phenyl-2-styrylquinolines,10 combretastatin A4,46 and its indolin-2-one-based analogue,47 as shown in Fig. 2, also contain the 3,4,5-trimethoxyphenyl fragment as the key pharmacophore. Thus, these insights from the in vitro anti-tumor activity might provide valuable information for further optimization of the series of derivatives, and hopefully, contribute to the development of new and effective anti-tumor candidates.
:
10) as eluent.
:
3 was heated at 100 °C in the air with stirring until a clear colourless liquid was obtained. After cooling to room temperature and vacuum drying for 5 h, the resulting 1,3-dimethylurea/L-(+)-tartaric acid deep eutectic solvent was sealed for later use.
:
3 mol mol−1) (1.5 g). The resulting reaction mixture was stirred at 80 °C for 6–8 hours (as monitored by TLC). After the reaction was completed, the mixture was diluted with an equal volume of water and extracted using EtOAc (3 × 5 mL). The deep eutectic solvent could be easily isolated after removing H2O from the aqueous layer under a vacuum and could be further used for the next reaction run. The combined organic layer was dried over Na2SO4, followed by evaporation of the solvent under reduced vacuum and washing with EtOH or column chromatography over silica gel using petroleum ether/EtOAc (12
:
1) as eluent to afford the desired 3a–q.
CH), 8.23 (d, J = 8.8 Hz, 1H, ArH), 8.02 (t, J = 7.6 Hz, 1H, ArH), 7.85 (d, J = 8.0 Hz, 2H, ArH), 7.80 (t, J = 7.2 Hz, 1H, ArH), 7.77 (d, J = 15.6 Hz, 1H, CH
CH), 7.62 (t, J = 7.6 Hz, 2H, ArH), 7.55 (t, J = 7.2 Hz, 1H, ArH), 4.75 (q, J = 7.2 Hz, 2H, CH2), 4.71 (q, J = 7.2 Hz, 2H, CH2), 1.67 (t, J = 7.2 Hz, 3H, CH3), 1.66 (t, J = 7.2 Hz, 3H, CH3). 13C NMR (100 MHz, CDCl3) δ 166.64, 165.99, 151.73, 148.26, 138.94, 136.61, 136.25, 131.08, 129.46, 128.56, 128.44, 127.41, 127.34, 125.13, 123.86, 123.48, 122.08, 62.08, 61.95, 13.88, 13.85. Anal. calcd for C23H21NO4: C, 73.58; H, 5.64; N, 3.73%. Found: C, 73.74; H, 5.61; N, 3.91%.
CH), 7.75 (t, J = 7.6 Hz, 1H, ArH), 7.63 (s, 1H, ArH), 7.61 (d, J = 7.2 Hz, 1H, ArH), 7.48 (t, J = 7.6 Hz, 1H, ArH), 7.34 (d, J = 7.2 Hz, 1H, ArH), 4.73–4.64 (m, 4H, CH2), 2.57 (s, 3H, CH3), 1.65 (t, J = 7.2 Hz, 6H, CH3). 13C NMR (100 MHz, CDCl3) δ 166.85, 166.15, 151.97, 148.42, 139.07, 138.15, 136.98, 136.36, 131.23, 129.60, 128.50, 128.18, 127.53, 125.28, 124.72, 123.79, 123.66, 122.22, 62.24, 62.11, 21.31, 14.03. Anal. calcd for C24H23NO4: C, 74.02; H, 5.95; N, 3.60%. Found: C, 73.81; H, 6.06; N, 3.83%.
CH), 8.23 (d, J = 7.6 Hz, 1H, ArH), 8.01 (t, J = 7.6 Hz, 1H, ArH), 7.79 (t, J = 7.6 Hz, 1H, ArH), 7.77 (d, J = 15.6 Hz, 1H, CH
CH), 7.75 (d, J = 8.0 Hz, 2H, ArH), 7.42 (d, J = 7.6 Hz, 2H, ArH), 4.75–4.67 (m, 4H, CH2), 2.59 (s, 3H, CH3), 1.68–1.64 (m, 6H, CH3). 13C NMR (100 MHz, CDCl3) δ 166.94, 166.24, 152.14, 148.50, 139.07, 138.95, 136.85, 133.73, 131.26, 129.63, 129.40, 127.53, 127.51, 125.34, 123.71, 123.06, 122.23, 62.29, 62.15, 21.34, 14.11, 14.08. Anal. calcd for C24H23NO4: C, 74.02; H, 5.95; N, 3.60%. Found: C, 74.19; H, 5.78; N, 3.67%.
CH), 8.13 (d, J = 8.4 Hz, 1H, ArH), 7.99 (d, J = 8.4 Hz, 1H, ArH), 7.77 (t, J = 8.4 Hz, 1H, ArH), 7.55 (t, J = 7.6 Hz, 1H, ArH), 7.45 (d, J = 15.2 Hz, 1H, CH
CH), 7.43 (s, 1H, ArH), 7.08 (d, J = 7.6 Hz, 1H, ArH), 7.02 (d, J = 7.6 Hz, 1H, ArH), 4.51–4.41 (m, 4H, CH2), 2.45 (s, 3H, CH3), 2.32 (s, 3H, CH3), 1.43–1.36 (m, 6H, CH3). 13C NMR (100 MHz, CDCl3) δ 167.00, 166.26, 152.20, 148.49, 139.02, 135.45, 135.30, 134.97, 134.13, 131.24, 130.47, 129.79, 129.51, 127.59, 126.63, 125.34, 124.97, 123.84, 122.29, 62.32, 62.19, 21.02, 19.53, 14.09, 14.08. Anal. calcd for C25H25NO4: C, 74.42; H, 6.25; N, 3.47%. Found: C, 74.24; H, 6.29; N, 3.31%.
CH), 8.09 (d, J = 7.6 Hz, 1H, ArH), 7.87 (t, J = 8.0 Hz, 1H, ArH), 7.64–7.60 (m, 2H, ArH), 7.49–7.45 (m, 2H, CH
CH, ArH), 7.23 (s, 1H, ArH), 4.62–4.55 (m, 4H, CH2), 2.37 (s, 6H, CH3), 1.54–1.52 (m, 6H, CH3). 13C NMR (100 MHz, CDCl3) δ 166.99, 166.27, 152.20, 148.52, 139.04, 137.74, 137.08, 136.79, 134.16, 131.25, 129.99, 129.64, 128.82, 127.48, 125.35, 125.19, 123.75, 122.87, 122.22, 62.29, 62.15, 19.77, 19.68, 14.12, 14.10. Anal. calcd for C25H25NO4: C, 74.42; H, 6.25; N, 3.47%. Found: C, 74.61; H, 6.13; N, 3.18%.
CH), 8.13 (d, J = 8.4 Hz, 1H, ArH), 7.98 (d, J = 8.4 Hz, 1H, ArH), 7.74 (t, J = 7.6 Hz, 1H, ArH), 7.64 (d, J = 16.0 Hz, 1H, CH
CH), 7.61 (d, J = 7.6 Hz, 1H, ArH), 7.53 (t, J = 7.6 Hz, 1H, ArH), 7.27 (t, J = 7.6 Hz, 1H, ArH), 6.95 (t, J = 7.2 Hz, 1H, ArH), 6.89 (d, J = 8.4 Hz, 1H, ArH), 4.49–4.40 (m, 4H, CH2), 3.87 (s, 3H, CH3), 1.42–1.36 (m, 6H, CH3). 13C NMR (100 MHz, CDCl3) δ 167.07, 166.27, 157.92, 152.51, 148.53, 138.81, 132.21, 131.13, 129.94, 129.80, 128.07, 127.47, 125.56, 125.30, 124.82, 123.98, 122.20, 120.63, 111.00, 62.27, 62.10, 55.45, 14.08. Anal. calcd for C24H23NO5: C, 71.10; H, 5.72; N, 3.45%. Found: C, 71.31; H, 5.60; N, 3.62%.
CH), 7.99 (d, 1H, J = 8.0 Hz, ArH), 7.78 (t, J = 7.6 Hz, 1H, ArH), 7.56 (d, J = 15.6 Hz, 1H, CH
CH), 7.54 (t, 1H, J = 8.0 Hz, ArH), 7.30 (t, J = 8.0 Hz, 1H, ArH), 7.22 (d, J = 7.6 Hz, 1H, ArH), 7.12 (s, 1H, ArH), 6.87 (d, J = 8.0 Hz, 1H, ArH), 4.47 (q, J = 7.2 Hz, 2H, CH2), 4.45 (q, J = 7.2 Hz, 2H, CH2), 3.82 (s, 3H, CH3), 1.41 (t, J = 7.2 Hz, 6H, CH3). 13C NMR (100 MHz, CDCl3) δ 166.79, 166.14, 159.73, 151.82, 148.42, 139.12, 137.85, 136.70, 131.26, 129.63, 129.56, 127.61, 125.30, 124.37, 123.67, 122.28, 120.10, 114.47, 112.77, 62.25, 62.12, 55.17, 14.05, 14.03. Anal. calcd for C24H23NO5: C, 71.10; H, 5.72; N, 3.45%. Found: C, 71.21; H, 5.87; N, 3.57%.
CH), 7.90 (d, J = 8.4 Hz, 1H, ArH), 7.75 (d, J = 8.8 Hz, 1H, ArH), 7.52 (t, J = 7.6 Hz, 1H, ArH), 7.42 (d, J = 16.0 Hz, 1H, CH
CH), 7.31 (t, J = 7.6 Hz, 1H, ArH), 7.00 (d, J = 7.6 Hz, 1H, ArH), 6.81 (t, J = 8.0 Hz, 1H, ArH), 6.63 (d, J = 8.0 Hz, 1H, ArH), 4.26–4.16 (m, 4H, CH2), 3.64 (s, 3H, CH3), 3.61 (s, 3H, CH3), 1.18–1.13 (m, 6H, CH3). 13C NMR (100 MHz, CDCl3) δ 166.76, 165.98, 152.85, 152.01, 148.26, 147.82, 138.63, 131.57, 130.94, 130.45, 129.63, 127.38, 125.62, 125.06, 123.78, 123.71, 122.03, 119.27, 112.34, 62.05, 61.93, 60.86, 55.58, 13.84. Anal. calcd for C25H25NO6: C, 68.95; H, 5.79; N, 3.22%. Found: C, 69.17; H, 5.83; N, 3.07%.
CH), 8.01 (d, J = 8.4 Hz, 1H, ArH), 7.86 (d, J = 8.4 Hz, 1H, ArH), 7.63 (t, J = 7.6 Hz, 1H, ArH), 7.49 (d, J = 15.6 Hz, 1H, CH
CH), 7.42 (t, J = 7.6 Hz, 1H, ArH), 7.03 (s, 1H, ArH), 6.72 (d, J = 7.2 Hz, 1H, ArH), 6.70 (d, J = 7.2 Hz, 1H, ArH), 4.37–4.28 (m, 4H, CH2), 3.72 (s, 3H, CH3), 3.65 (s, 3H, CH3), 1.30–1.25 (m, 6H, CH3). 13C NMR (100 MHz, CDCl3) δ 166.93, 166.15, 153.42, 152.42, 152.29, 148.42, 138.73, 131.96, 131.04, 129.72, 127.42, 126.19, 125.20, 125.08, 123.88, 122.13, 115.06, 113.05, 112.18, 62.18, 62.00, 56.02, 55.65, 13.99, 13.98. Anal. calcd for C25H25NO6: C, 68.95; H, 5.79; N, 3.22%. Found: C, 68.73; H, 5.64; N, 3.26%.
CH), 8.01 (d, J = 8.8 Hz, 1H, ArH), 7.80 (t, J = 7.6 Hz, 1H, ArH), 7.58 (t, J = 7.6 Hz, 1H, ArH), 7.47 (d, J = 15.2 Hz, 1H, CH
CH), 7.23 (d, J = 8.4 Hz, 1H, ArH), 7.16 (s, 1H, ArH), 6.90 (d, J = 8.4 Hz, 1H, ArH), 4.54–4.45 (m, 4H, CH2), 3.95 (s, 3H, CH3), 3.92 (s, 3H, CH3), 1.47 (t, J = 7.2 Hz, 6H, CH3). 13C NMR (100 MHz, CDCl3) δ 166.99, 166.25, 152.14, 149.93, 149.02, 148.52, 139.08, 136.77, 131.28, 129.60, 129.56, 127.45, 125.36, 123.62, 122.18, 122.10, 121.29, 111.12, 109.88, 62.30, 62.11, 55.89, 55.83, 14.13, 14.08. Anal. calcd for C25H25NO6: C, 68.95; H, 5.79; N, 3.22%. Found: C, 68.69; H, 5.86; N, 3.14%.
CH), 7.79 (t, J = 7.6 Hz, 1H, ArH), 7.58 (t, J = 7.6 Hz, 1H, ArH), 7.49 (d, J = 16.0 Hz, 1H, CH
CH), 6.84 (s, 2H, ArH), 4.53–4.44 (m, 4H, CH2), 3.91 (s, 6H, CH3), 3.88 (s, 3H, CH3), 1.45 (t, J = 7.2 Hz, 6H, CH3). 13C NMR (100 MHz, CDCl3) δ 166.96, 166.25, 153.32, 151.85, 148.51, 139.26, 138.92, 136.90, 132.18, 131.43, 129.62, 127.69, 125.42, 123.62, 123.49, 122.31, 104.67, 62.40, 62.20, 60.98, 56.10, 14.18, 14.12. Anal. calcd for C26H27NO7: C, 67.09; H, 5.85; N, 3.01%. Found: C, 66.91; H, 6.04; N, 3.17%.
CH), 8.14 (d, J = 8.4 Hz, 1H, ArH), 7.98 (d, J = 8.4 Hz, 1H, ArH), 7.77 (t, J = 8.4 Hz, 1H, ArH), 7.70 (d, J = 7.2 Hz, 1H, ArH), 7.58 (d, J = 15.6 Hz, 1H, CH
CH), 7.54 (t, J = 8.4 Hz, 1H, ArH), 7.38 (d, J = 7.6 Hz, 1H, ArH), 7.24 (t, J = 7.6 Hz, 1H, ArH), 7.20 (t, J = 7.6 Hz, 1H, ArH), 4.50 (q, J = 7.6 Hz, 2H, CH2), 4.43 (q, J = 7.6 Hz, 2H, CH2), 1.42 (t, J = 7.6 Hz, 3H, CH3), 1.38 (t, J = 7.6 Hz, 3H, CH3). 13C NMR (100 MHz, CDCl3) δ 166.78, 166.19, 151.67, 148.50, 139.31, 134.76, 134.47, 132.88, 131.36, 129.99, 129.95, 129.58, 127.88, 127.29, 126.87, 126.84, 125.31, 123.59, 122.43, 62.33, 62.23, 14.09, 14.06. Anal. calcd for C23H20ClNO4: C, 67.40; H, 4.92; N, 3.42%. Found: C, 67.23; H, 4.79; N, 3.33%.
CH), 7.79 (t, J = 8.0 Hz, 1H, ArH), 7.74 (s, 1H, ArH), 7.58 (d, J = 15.6 Hz, 1H, CH
CH), 7.54 (d, J = 7.6 Hz, 1H, ArH), 7.51 (d, J = 8.0 Hz, 1H, ArH), 7.43 (d, J = 8.0 Hz, 1H, ArH), 7.24 (t, J = 7.2 Hz, 1H, ArH), 4.52–4.43 (m, 4H, CH2), 1.44 (t, J = 7.2 Hz, 6H, CH3). 13C NMR (100 MHz, CDCl3) δ 166.43, 165.92, 151.24, 148.21, 139.20, 138.40, 134.92, 131.29, 131.20, 129.97, 129.92, 129.49, 127.62, 125.96, 125.24, 125.13, 123.28, 122.59, 122.20, 62.10, 62.03, 13.91, 13.84. Anal. calcd for C23H20BrNO4: C, 60.81; H, 4.44; N, 3.08%. Found: C, 60.69; H, 4.25; N, 3.16%.
CH), 8.14 (d, J = 8.4 Hz, 1H, ArH), 7.97 (d, J = 8.4 Hz, 1H, ArH), 7.94 (d, J = 8.0 Hz, 1H, ArH), 7.79 (d, J = 15.6 Hz, 1H, CH
CH), 7.77 (t, J = 7.6 Hz, 1H, ArH), 7.61–7.55 (m, 3H, CH
CH, ArH), 7.45 (t, J = 7.6 Hz, 1H, ArH), 4.50 (q, J = 7.2 Hz, 2H, CH2), 4.44 (q, J = 7.2 Hz, 2H, CH2), 1.41 (t, J = 7.6 Hz, 3H, CH3), 1.37 (t, J = 7.6 Hz, 3H, CH3). 13C NMR (100 MHz, CDCl3) δ 166.30, 165.87, 150.78, 148.25, 148.20, 139.35, 132.80, 132.10, 131.44, 131.25, 129.83, 128.81, 128.63, 128.51, 127.88, 125.02, 124.41, 123.02, 122.29, 62.06, 62.00, 13.81, 13.73. Anal. calcd for C23H20N2O6: C, 65.71; H, 4.79; N, 6.66%. Found: C, 65.48; H, 4.84; N, 6.52%.
CH), 7.98 (d, J = 8.4 Hz, 1H, ArH), 7.80 (t, J = 8.4 Hz, 1H, ArH), 7.78 (d, J = 15.6 Hz, 1H, CH
CH), 7.70 (d, J = 8.4 Hz, 2H, ArH), 7.60 (t, J = 8.0 Hz, 1H, ArH), 4.52–4.42 (m, 4H, CH2), 1.44–1.38 (m, 6H, CH3). 13C NMR (100 MHz, CDCl3) δ 166.48, 166.07, 151.00, 148.47, 147.48, 142.85, 139.84, 134.05, 131.69, 129.83, 128.42, 128.28, 127.98, 125.46, 124.06, 123.43, 122.68, 62.43, 62.39, 14.09. Anal. calcd for C23H20N2O6: C, 65.71; H, 4.79; N, 6.66%. Found: C, 65.64; H, 4.82; N, 6.81%.
CH), 8.22 (d, J = 8.8 Hz, 1H, ArH), 8.03 (d, J = 8.4 Hz, 2H, ArH), 7.89 (d, J = 8.0 Hz, 1H, ArH), 7.85 (t, J = 8.0 Hz, 1H, ArH), 7.78 (d, J = 16.0 Hz, 1H, CH
CH), 7.75 (t, J = 8.0 Hz, 1H, ArH), 7.64 (t, J = 8.0 Hz, 1H, ArH), 7.59 (t, J = 8.0 Hz, 1H, ArH), 4.56 (q, J = 7.2 Hz, 2H, CH2), 4.51 (q, J = 7.2 Hz, 2H, CH2), 1.48 (t, J = 7.2 Hz, 3H, CH3), 1.45 (t, J = 7.2 Hz, 3H, CH3). 13C NMR (100 MHz, CDCl3) δ 166.64, 166.14, 151.16, 150.46, 148.51, 147.23, 139.66, 135.04, 131.68, 131.58, 130.69, 130.04, 129.65, 128.61, 128.29, 128.16, 127.77, 127.30, 127.26, 125.36, 123.29, 122.58, 62.37, 62.34, 14.10, 14.03. Anal. calcd for C26H21ClN2O4: C, 67.75; H, 4.59; N, 6.08%. Found: C, 67.86; H, 4.62; N, 5.88%.
CH), 8.38 (s, 1H, ArH), 8.23 (d, J = 8.4 Hz, 1H, ArH), 8.04 (d, J = 8.0 Hz, 1H, ArH), 7.92 (d, J = 8.4 Hz, 1H, ArH), 7.86 (t, J = 8.0 Hz, 1H, ArH), 7.76 (d, J = 15.6 Hz, 1H, CH
CH), 7.64 (s, 1H, ArH), 7.64 (t, J = 7.2 Hz, 1H, ArH), 7.58 (d, J = 8.4 Hz, 1H, ArH), 4.57–4.46 (m, 4H, CH2), 2.55 (s, 3H, CH3), 1.49–1.42 (m, 6H, CH3). 13C NMR (100 MHz, CDCl3) δ 161.51, 161.02, 146.10, 144.44, 143.32, 140.74, 134.53, 132.22, 129.34, 127.91, 126.81, 126.48, 124.86, 124.35, 123.19, 123.03, 122.81, 122.17, 121.47, 120.23, 118.18, 117.43, 57.27, 57.22, 16.44, 8.98, 8.93. Anal. calcd for C27H23ClN2O4: C, 68.28; H, 4.88; N, 5.90%. Found: C, 68.47; H, 4.63; N, 5.93%.
Footnote |
| † Electronic supplementary information (ESI) available. See DOI: https://doi.org/10.1039/d4ra04588b |
| This journal is © The Royal Society of Chemistry 2024 |